Phase 2 study of HDAC inhibitor tucidinostat in combination with anti-PD-1 antibody in patients with locally advanced or metastatic urothelial carcinoma

被引：0
|
作者：
Liu, Zhuowei
Jiang, Lijuan
Li, Xiangdong
Ye, Yunlin
Wu, Zhiming
An, Xin
Shi, Yanxia
Yao, Kai
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Dept Urol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16563
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer
    O'Malley, David M.
    Oaknin, Ana
    Monk, Bradley J.
    Selle, Frederic
    Rojas, Carlos
    Gladieff, Laurence
    Berton, Dominique
    Leary, Alexandra
    Moore, Kathleen N.
    Estevez-Diz, Maria D. P.
    Hardy-Bessard, Anne-Claire
    Alexandre, Jerome
    Opperman, Christina P.
    de Azevedo, Carla Rameri A. S.
    Randall, Leslie M.
    Feliu, Waldo Ortuzar
    Ancukiewicz, Marek
    Ray-Coquard, Isabelle
    GYNECOLOGIC ONCOLOGY, 2021, 163 (02) : 274 - 280
  • [42] ATLAS: a phase 2, open-label study of rucaparib in patients with locally advanced (unresectable) or metastatic urothelial carcinoma
    Feyerabend, S.
    Boegemann, M.
    Goebell, P. J.
    Stoeckle, M.
    Nepert, D.
    Wride, K.
    Thomas, D.
    Loehr, A.
    Simmons, A.
    Grivas, P.
    Chowdhury, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 324 - 324
  • [43] Vinflunine in Platinum-Pretreated Patients With Locally Advanced or Metastatic Urothelial Carcinoma Results of a Large Phase 2 Study
    Vaughn, David J.
    Srinivas, Sandy
    Stadler, Walter M.
    Pili, Roberto
    Petrylak, Daniel
    Sternberg, Cora N.
    Smith, David C.
    Ringuette, Sarah
    de Wit, Edwin
    Pautret, Virginie
    George, Claude
    CANCER, 2009, 115 (18) : 4110 - 4117
  • [44] Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Final efficacy and safety data.
    Owonikoko, Taofeek Kunle
    Papadopoulos, Kyriakos P.
    Johnson, Melissa Lynne
    Martin, Marta Gil
    Moreno, Victor
    Salama, April K. S.
    Calvo, Emiliano
    Yee, Nelson S.
    Safran, Howard
    Gonzalez-Martin, Antonio
    Aljumaily, Raid
    Mahadevan, Daruka
    Niu, Jiaxin
    Mohan, Kosalai Kal
    Li, Jingjin
    Stankevich, Elizabeth
    Lowy, Israel
    Fury, Matthew G.
    Babiker, Hani M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] A PHASE 1B/2 STUDY OF A NOVEL ANTI-CTLA-4 NEOBODYTM ADG116 MONOTHERAPY AND IN COMBINATION WITH TORIPALIMAB (TORI; ANTI-PD-1 ANTIBODY) IN PATIENTS WITH ADVANCED/METASTATIC SOLID TUMORS
    Park, John
    Hsien, Matthew
    Richardson, Gary
    Tolcher, Anthony
    Chon, Hong Jae
    Shin, Sang Joon
    Lim, Ho Yeong
    Hamid, Anis
    Li, Daneng
    Shi, Kristine
    Zheng, Songmao
    Liu, Guizhong
    Li, Ai
    Zhu, Lvyu
    Dai, Ruby
    Peng, Wei
    Lowe, Dana
    Luo, Peter
    Zha, Jiping
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A785 - A785
  • [46] Phase Ib study of BI 836880 (VEGF/Ang2 inhibitor) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Meyer, Tim
    Ledin, Evgeny
    Kim, Dong-Wan
    Ghiringhelli, Francois
    Serwatowski, Piotr
    Voskoboynik, Mark
    Landsteiner, Harald Timotheus
    Chen, Victoria
    Jayadeva, Girish
    Macarulla, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [47] Initial results of a phase 1b/2 study of ADG126 (a masked anti-CTLA-4 SAFEbody ®) in combination with pembrolizumab (an anti-PD-1 antibody) in patients with advanced/metastatic solid tumors
    Li, Daneng
    Sharma, Sunil
    She, Kristine
    Li, Wenda
    Li, Ai
    Zheng, Songmao
    Liu, Guizhong
    Ndukwo, Ogon
    Hu-Lowe, Dana
    Chisamore, Michael
    Luo, Peter
    Zha, Jiping
    Patel, Manish R.
    CANCER RESEARCH, 2023, 83 (08)
  • [48] Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients with Malignant Mesothelioma
    Kindler, Hedy Lee
    Karrison, Theodore
    Khattri, Arun
    Zuo, Zhixiang
    Sulai, Nanna
    Rose, Buerkley
    Ahmad, Mehwish I.
    Armato, Samuel
    Salgia, Ravi
    Seiwert, Tanguy
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S630 - S630
  • [49] Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma
    Chen, Jiaqi
    Zhang, Ding
    Yuan, Ying
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (03) : 579 - 590
  • [50] Enhancing efficacy of anti-PD-1 antibody by combination with an HDAC/PI3K dual inhibitor in a mouse model of melanoma
    Saijo, Ken
    Imai, Hiroo
    Chikamatsu, Sonoko
    Kasahara, Yuki
    Shirota, Hidekazu
    Katoh, Tadashi
    Ishioka, Chikashi
    CANCER SCIENCE, 2018, 109 : 412 - 412
12345